Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Edward F Jackson

Showing results (41-50 of 58) with videos related to

Pageof 6
Sort By:
Translational Oncology|December 4, 2009
Quantitative imaging to assess tumor response to therapy: common themes of measurement, truth data, and error sourcesCharles R Meyer, Samuel G Armato, Charles P Fenimore, et al.
Journal of Magnetic Resonance Imaging : JMRI|July 30, 2019
ACR guidance document on MR safe practices: Updates and critical information 2019, Todd D Greenberg, Michael N Hoff, et al.
The Lancet. Oncology|October 14, 2011
Phase 1-2 study of docetaxel plus aflibercept in patients with recurrent ovarian, primary peritoneal, or fallopian tube cancerRobert L Coleman, Linda R Duska, Pedro T Ramirez, et al.
Journal of Magnetic Resonance Imaging : JMRI|November 20, 2018
Quantitative imaging biomarkers alliance (QIBA) recommendations for improved precision of DWI and DCE-MRI derived biomarkers in multicenter oncology trialsAmita Shukla-Dave, Nancy A Obuchowski, Thomas L Chenevert, et al.
Neuro-Oncology|March 4, 2008
Phase II trial of irinotecan and thalidomide in adults with recurrent glioblastoma multiformeVinay K Puduvalli, Pierre Giglio, Morris D Groves, et al.
Oncotarget|November 7, 2014
Targeting hypoxia-inducible factor-1α (HIF-1α) in combination with antiangiogenic therapy: a phase I trial of bortezomib plus bevacizumabGerald S Falchook, Jennifer J Wheler, Aung Naing, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 25, 2011
Phase II study of aflibercept in recurrent malignant glioma: a North American Brain Tumor Consortium studyJohn F de Groot, Kathleen R Lamborn, Susan M Chang, et al.
Insights Into Imaging|August 31, 2019
Validated imaging biomarkers as decision-making tools in clinical trials and routine practice: current status and recommendations from the EIBALL* subcommittee of the European Society of Radiology (ESR)Nandita M deSouza, Eric Achten, Angel Alberich-Bayarri, et al.
Radiology|January 19, 2021
Linearity and Bias of Proton Density Fat Fraction as a Quantitative Imaging Biomarker: A Multicenter, Multiplatform, Multivendor Phantom StudyHouchun H Hu, Takeshi Yokoo, Mustafa R Bashir, et al.
Plos One|June 30, 2021
Multi-site, multi-platform comparison of MRI T1 measurement using the system phantomKathryn E Keenan, Zydrunas Gimbutas, Andrew Dienstfrey, et al.
Pageof 6

Showing results (41-50 of 58) with videos related to

Sort By:
Pageof 6
Translational Oncology|December 4, 2009
Quantitative imaging to assess tumor response to therapy: common themes of measurement, truth data, and error sourcesCharles R Meyer, Samuel G Armato, Charles P Fenimore, et al.
Journal of Magnetic Resonance Imaging : JMRI|July 30, 2019
ACR guidance document on MR safe practices: Updates and critical information 2019, Todd D Greenberg, Michael N Hoff, et al.
The Lancet. Oncology|October 14, 2011
Phase 1-2 study of docetaxel plus aflibercept in patients with recurrent ovarian, primary peritoneal, or fallopian tube cancerRobert L Coleman, Linda R Duska, Pedro T Ramirez, et al.
Journal of Magnetic Resonance Imaging : JMRI|November 20, 2018
Quantitative imaging biomarkers alliance (QIBA) recommendations for improved precision of DWI and DCE-MRI derived biomarkers in multicenter oncology trialsAmita Shukla-Dave, Nancy A Obuchowski, Thomas L Chenevert, et al.
Neuro-Oncology|March 4, 2008
Phase II trial of irinotecan and thalidomide in adults with recurrent glioblastoma multiformeVinay K Puduvalli, Pierre Giglio, Morris D Groves, et al.
Oncotarget|November 7, 2014
Targeting hypoxia-inducible factor-1α (HIF-1α) in combination with antiangiogenic therapy: a phase I trial of bortezomib plus bevacizumabGerald S Falchook, Jennifer J Wheler, Aung Naing, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 25, 2011
Phase II study of aflibercept in recurrent malignant glioma: a North American Brain Tumor Consortium studyJohn F de Groot, Kathleen R Lamborn, Susan M Chang, et al.
Insights Into Imaging|August 31, 2019
Validated imaging biomarkers as decision-making tools in clinical trials and routine practice: current status and recommendations from the EIBALL* subcommittee of the European Society of Radiology (ESR)Nandita M deSouza, Eric Achten, Angel Alberich-Bayarri, et al.
Radiology|January 19, 2021
Linearity and Bias of Proton Density Fat Fraction as a Quantitative Imaging Biomarker: A Multicenter, Multiplatform, Multivendor Phantom StudyHouchun H Hu, Takeshi Yokoo, Mustafa R Bashir, et al.
Plos One|June 30, 2021
Multi-site, multi-platform comparison of MRI T1 measurement using the system phantomKathryn E Keenan, Zydrunas Gimbutas, Andrew Dienstfrey, et al.
Pageof 6